APA (7th ed.) Citation

S, B., M, H., O, N., Jr, A. L., T, G., M, K., . . . JG, B. (2026). Arlocabtagene autoleucel-a GPRC5D-targeted CAR T-cell therapy in heavily pretreated relapsed/refractory multiple myeloma. Blood. https://doi.org/10.1182/blood.2025030750

Chicago Style (17th ed.) Citation

S, Bal, et al. "Arlocabtagene Autoleucel-a GPRC5D-targeted CAR T-cell Therapy in Heavily Pretreated Relapsed/refractory Multiple Myeloma." Blood 2026. https://doi.org/10.1182/blood.2025030750.

MLA (9th ed.) Citation

S, Bal, et al. "Arlocabtagene Autoleucel-a GPRC5D-targeted CAR T-cell Therapy in Heavily Pretreated Relapsed/refractory Multiple Myeloma." Blood, 2026, https://doi.org/10.1182/blood.2025030750.